# US 2013/0289050 A1 · Inhibitors of beta-secretase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0289050 A1
- Document ID: US20130289050A1
- Status: Published application
- Kind: A1
- Application number: 13/784,032
- Filed: 2013-03-04
- Published: 2013-10-31
- Earliest claimed: 2012-03-05
- Assignees: Vitae Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
- Inventors: Yuri Bukhtiyarov; Salvacion Cacatian; Lawrence Wayne Dillard; Cornelia Dorner-Ciossek; Klaus Fuchs; Lanqi Jia; Deepak S. Lala; Angel Morales-Ramos; Jonathan Reeves; Suresh B. Singh; Shanker Venkatraman; Zhenrong Xu; Jing Yuan; Yi Zhao; Yajun Zheng; Georg Rast
- Web page: https://patentgrep.com/patent/US20130289050A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 49/697: containing six-membered aromatic rings
- C07C 49/747: containing six-membered aromatic rings
- C07C 49/755: a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
- C07C 229/50: with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
- C07C 255/47: to carbon atoms of rings being part of condensed ring systems
- C07C 313/06: Sulfinamides
- C07C 331/14: having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07D 235/02: condensed with carbocyclic rings or ring systems
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 407/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.

## Claims

### Claim 1

A compound represented by a structural formula selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use as a medicament.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising at least one compound according to claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.

### Claim 4 (depends on 1)

A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of a BACE1 mediated disorder or disease.

### Claim 5 (depends on 4)

A compound or a pharmaceutically acceptable salt thereof for use according to claim 4, wherein the BACE1 mediated disorder or disease is selected from the group consisting of a neurodegenerative disorder, cognitive decline, cognitive impairment, dementia, and disease characterized by the production of β-amyloid deposits or neurofibrillary tangles.

### Claim 6 (depends on 5)

A compound or a pharmaceutically acceptable salt thereof for use according to claim 5, wherein the disorder or disease is selected from the group consisting of Alzheimer's disease, Trisomy 21 (Down Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), senile dementia, cerebral amyloid angiopathy, degenerative dementia, dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, diffuse Lewy body type of Alzheimer's disease, dry age related macular degeneration (AMD), and glaucoma.

### Claim 7 (depends on 6)

A compound or a pharmaceutically acceptable salt thereof for use according to claim 6, wherein the disorder or disease is Alzheimer's disease.

### Claim 8 (depends on 6)

A compound or a pharmaceutically acceptable salt thereof for use according to claim 6, wherein the disorder or disease is glaucoma.

### Claim 9 (depends on 1)

Use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a BACE1 mediated disorder in a subject.

### Claim 10 (depends on 9)

Use of a compound according to claim 9 or a pharmaceutically acceptable salt thereof, wherein the BACE1 mediated disease or disorder is selected from the group consisting of a neurodegenerative disorder, cognitive decline, cognitive impairment, dementia, and disease characterized by the production of β-amyloid deposits or neurofibrillary tangles.

### Claim 11 (depends on 10)

Use of a compound according to claim 10 or a pharmaceutically acceptable salt thereof, wherein the disorder or disease is selected from the group consisting of Alzheimer's disease, Trisomy 21 (Down Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), senile dementia, cerebral amyloid angiopathy, degenerative dementia, dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, diffuse Lewy body type of Alzheimer's disease, dry age related macular degeneration (AMD), and glaucoma.

### Claim 12 (depends on 11)

Use of a compound according to claim 11 or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is Alzheimer's disease.

### Claim 13 (depends on 11)

Use of a compound according to claim 11 or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is glaucoma.

### Claim 14 (depends on 1)

A method of treating a BACE1 mediated disorder or disease in a subject, comprising administering to the subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the BACE1 mediated disorder or disease is selected from the group consisting of neurodegenerative disorder, cognitive decline, cognitive impairment, dementia, and disease characterized by the production of β-amyloid deposits or neurofibrillary tangles.

### Claim 16 (depends on 15)

The method of claim 15, wherein the disorder or disease is selected from the group consisting of Alzheimer's disease, Trisomy 21 (Down Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-type (HCHWA-D), senile dementia, cerebral amyloid angiopathy, degenerative dementia, dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, diffuse Lewy body type of Alzheimer's disease, dry age related macular degeneration (AMD), and glaucoma.

### Claim 17 (depends on 16)

The method of claim 16, wherein the disorder or disease is Alzheimer's disease.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the disorder or disease is glaucoma.

### Claim 19

A compound selected from the group consisting of:
or a salt thereof.
